FDA Hits Pause on Capricor's Duchenne Cell Therapy — Again

The U.S. Food and Drug Administration has pushed back its decision date on deramiocel, Capricor Therapeutics' cell therapy for Duchenne muscular dystrophy, giving itself more time to review additional data the company submitted.

Capricor announced the extension on Monday, according to Endpoints News, which reported that the agency delayed the therapy's PDUFA date — the target date by which the FDA aims to rule on a drug application — in order to examine new data supporting a narrower use of the treatment.

BioPharma Dive reported that the FDA is now reviewing an updated application for deramiocel with what it described as a "refined" indication. In practice, that means Capricor is no longer asking regulators to approve the therapy as broadly as it originally proposed, and is instead seeking a green light for a more specific group of patients.

Endpoints characterized deramiocel as a "problematic" Duchenne therapy and the revised target as "a more niche indication" — language that signals the program has already faced difficulty in its path through the agency.

Duchenne muscular dystrophy is a rare, degenerative muscle disease, and the small number of approved treatments makes each regulatory decision consequential for patients and families watching the pipeline. Narrowing an indication is a common strategy when a company's evidence looks stronger in one subgroup than across the whole patient population, but it also shrinks the commercial opportunity — a meaningful risk for a small biotech whose value rests largely on a single lead program.

The delay was disclosed in the same week's biotech news cycle that included a startup co-founded by Vivek Ramaswamy taking what BioPharma Dive called "a speedy path to the public markets," a reminder of how uneven the sector's fortunes can look from one day to the next.

It matters because a rare-disease community with few options now waits longer for an answer, and because the outcome will show how much flexibility the FDA is willing to extend to cell therapies whose evidence is strongest in a narrow slice of patients.